Lasa Supergenerics Ltd
LASA

Lasa Supergenerics Ltd (LASA)

₹381.33%

Key Stats

₹37.05
Day's Price Range
₹39.05
₹25.25
52-Week Price Range
₹84.15
1 Month Return6.53 %
3 Month Return45.91 %
1 Year Return-48.95 %

Company Financials

  • Annual
Value in ₹ crore

Peer Comparsion

PE
Rank 300
EPS
Rank 304
BVPS
Rank 327
Dividend Yield
Rank 178
ROE
Rank 416
1.67%
Price To Book Ratio
Rank 263
Debt To Asset
Rank 317

Company Information

Lasa Supergenerics Limited was incorporated on March 11 2016. The Company is primarily engaged in the business of manufacturing trading producing processing preparing treating chemicals API Pharmaceuticals drugs etc. The Company is a vertically integrated group spanning the entire veterinary animal and human healthcare value chainfrom discoverytodelivery with established credentials in research manufacturing and global marketing. The Company is a veterinary API manufacturing entity which was acquired in April 2012. The manufacturing facility is located at Mahad Chiplun in the Konkan region of Maharashtra. It specialises in catalyst chemistry and manufactures anthelmintic / veterinary API products with largest production capabilities and product categories in India. To efficiently control the supply chain the Company is fully backward integrated for its key moleculesfrom discovery research up to fullscale bulk production. The Companys marketing footprint is entrenched across developing markets in multiple countries. Similarly the group expects to augment its export footprint significantly in width and depth in the future.The Company announced the launching of 2 new block buster products with alltime strong segment Oxycozanide. Oxyclozanide is an anthelmintic used in the treatment and control of fascioliasis a topical worm infection in ruminants mainly domestic animals such as cattle especially buffalos in farm sheep and goats. For this the Company is setting up capacity in a brown field expansion at its Chiplun unit with a total capacity of 20 MT. It has got huge demand all over the globe as it is manufactured and have strong entry barriers. Likewise this product fits in product selection criteria through which the Company is confident of grabbing significant market share.Due to floods and fire in the company units the launch of another block buster product was deferred and commercialization of Oxyclozanide prolonged for some time to accommodate existing products in the company. The company received WHO Certificate of Good Manufacturing Practices from the Food and Drug Administration authorities for its manufacturing facility situated at Khed Ratnagiri.The Company has alliances with leading Indian and global animal health care conglomerates and uses Good Manufacturing Practice GMP and worldclass technologies in its operations. The Company is managed by a consortium of technocrats including its Chairman and Managing Director Mr. Omkar P. Herlekar who are impelled by passion and propelled by niche innovation. The leadership team which is guided by these values is well positioned to lead into the future.The Company is determined to achieve of becoming a leading force in the niche animal health care solutions. The objective on which it was founded have always inspired sustainable growth through innovation and shall continue to do so. Today the Company is the leading manufacturer player in veterinary APIs in India with a wellestablished brand known for its highquality products amongst various customers.
OrganisationLasa Supergenerics Ltd
HeadquartersRaigad
IndustryPharmaceuticals